Electromed (ELMD) investor relations material

Executive summary

• Achieved twelfth consecutive quarter of year-over-year revenue and net income growth, reflecting strong business fundamentals, operational execution, and growing recognition of SmartVest therapy for bronchiectasis.

• Recognized by Time Magazine as one of America's Top 100 Growth Leaders for revenue growth and financial security.

• Completed manufacturing optimization plan and implemented a new CRM system, enhancing sales productivity and operational efficiencies.

• Continued investment in commercial infrastructure, including sales force expansion and new CRM system, to support long-term growth.

• Net revenues for the quarter ended September 30, 2025, increased 15.1% year-over-year to $16,887,000, driven by growth in homecare, hospital, and distributor channels.

Financial highlights

• Q1 revenue reached $16.9 million, up 15.1% year-over-year, with broad-based growth across all channels.

• Operating income rose 38% year-over-year to $2.7 million, representing 15.8% of revenue.

• Net income increased 44.9% to $2.1 million, or $0.25 per diluted share, compared to $1.5 million, or $0.16 per share, in the prior year.

• Gross profit was $13.2 million (78.1% of net revenues), up from $11.5 million (78.3%).

• Cash balance at quarter-end was $14.1 million, with no debt and working capital of $35.8 million.

Outlook and guidance

• Management expects to continue double-digit top-line growth and expanded operating leverage for fiscal 2026.

• Ongoing investments in commercial and operational initiatives, including sales force and infrastructure, are expected to drive future growth.

• Current working capital and available credit are expected to be sufficient for operational and capital needs for at least the next twelve months.

• Management believes the company is well-positioned for continued growth and attractive shareholder returns in fiscal 2026 and beyond.